Grufity logo
Grufity logo
LIXT

LIXT - Lixte Biotechnology Holdings, Inc. Stock Price, Fair Value and News

$4.17+0.15 (+3.73%)
Market Closed as of 30 Jul 2026, 04:00 pm ET

Price Targets

LIXT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIXT Price Action

Last 7 days

-16.4%

Last 30 days

-29.5%

Last 90 days

30.5%

Trailing 12 Months

12.8%

LIXT RSI Chart

LIXT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIXT Valuation

Market Cap

51.6M

Price/Earnings (Trailing)

-7.02

Price/Sales (Trailing)

9.0K

Price/Free Cashflow

-11.92

LIXT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

LIXT Fundamentals

LIXT Revenue

Revenue (TTM)

7.4K

LIXT Earnings

Earnings (TTM)

-7.4M

Earnings Growth (Yr)

-180.12%

Earnings Growth (Qtr)

23.93%

LIXT Profitability

Operating Margin

-27539.40%

Return on Equity

-92.59%

Return on Assets

-67.71%

Free Cashflow Yield

-8.39%

LIXT Investor Care

Shares Dilution (1Y)

401.03%

Diluted EPS (TTM)

-1.14

Revenue & Growth

How Lixte Biotechnology Holdings, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20257.2K--7.4K
2024---7.0K
2023----
2022----
2021----
2020----
2019----
2018----
2017----
2016----
2015---200.0K
2010----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Lixte Biotechnology Holdings, Inc.

LIXT
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
 CEO
 WEBSITEhttps://lixte.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3

Lixte Biotechnology Holdings, Inc. Frequently Asked Questions

LIXT is the stock ticker symbol of Lixte Biotechnology Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Jul 30 2026, market cap of Lixte Biotechnology Holdings, Inc. is 51.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Jul 30 2026, LIXT's PE ratio (Price to Earnings) is -7.02 and Price to Sales (PS) ratio is 9.03 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIXT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Lixte Biotechnology Holdings, Inc. has provided -0.084 (multiply by 100 for percentage) rate of return.